AuroMedics Pharma – Recall of Linezolid Injection

- On December 26, 2017, the FDA announced a voluntary recall of one lot of AuroMedics Pharma's linezolid injection due to a product complaint in which the contents of one flexible bag from the recalled lot was found to contain white particulate matter identified as mold.

- The recalled lot was distributed May 15, 2017 through August 14, 2017.

Product Description	NDC #	Lot # (expiration date)
Linezolid injection 600 mg/300 mL flexible bags	55150-242-51	CLZ160007 (August 2018)

- Linezolid injection is indicated for the treatment of infections caused by susceptible strains of certain microorganisms of various conditions, including pneumonia, skin and skin structure infections, and vancomycin-resistant *Enterococcus faecium* infections.

- Use of a non-sterile injectable product could result in fatal infections in a broad array of patients. To date, AuroMedics Pharma has not received reports of any adverse events or identifiable safety concerns attributed to this recall.

- Patients should contact their healthcare provider if they have experienced any problems that may be related to taking or using the recalled linezolid injection.

- Anyone with recalled product should stop use and distribution, quarantine the product, and return to the place of purchase. Contact Inmar at **1-800-967-5952** for return information. For general questions regarding this recall, contact Aurobindo (affiliate of AuroMedics) at **1-866-850-2876**.